Inventiva Future Growth
Future criteria checks 2/6
Inventiva is forecast to grow earnings and revenue by 21.7% and 49.1% per annum respectively while EPS is expected to grow by 38.1% per annum.
Key information
21.7%
Earnings growth rate
38.1%
EPS growth rate
Biotechs earnings growth | 28.3% |
Revenue growth rate | 49.1% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 05 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement
Jul 08Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause
Feb 22Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment
Sep 21Inventiva lays out trial design for late-stage lanifibranor study in NASH
Jan 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 34 | -108 | -24 | -6 | 6 |
12/31/2025 | 15 | -92 | -67 | -75 | 7 |
12/31/2024 | 3 | -107 | -98 | -109 | 6 |
12/31/2023 | 23 | -110 | -82 | -82 | N/A |
9/30/2023 | 23 | -95 | -73 | -73 | N/A |
6/30/2023 | 22 | -80 | -64 | -64 | N/A |
3/31/2023 | 20 | -67 | -55 | -54 | N/A |
12/31/2022 | 19 | -54 | -45 | -45 | N/A |
9/30/2022 | 14 | -55 | -50 | -49 | N/A |
6/30/2022 | 10 | -56 | -55 | -54 | N/A |
3/31/2022 | 10 | -56 | -54 | -53 | N/A |
12/31/2021 | 9 | -50 | -48 | -48 | N/A |
9/30/2021 | 7 | -45 | -46 | -45 | N/A |
6/30/2021 | 6 | -41 | -44 | -43 | N/A |
3/31/2021 | 5 | -36 | -35 | -35 | N/A |
12/31/2020 | 5 | -34 | -31 | -31 | N/A |
9/30/2020 | 7 | -29 | -24 | -24 | N/A |
6/30/2020 | 10 | -25 | -17 | -17 | N/A |
3/31/2020 | 10 | -27 | -23 | -23 | N/A |
12/31/2019 | 11 | -30 | -29 | -28 | N/A |
9/30/2019 | 9 | -34 | -33 | -33 | N/A |
6/30/2019 | 7 | -37 | -38 | -38 | N/A |
3/31/2019 | 8 | -35 | -36 | -35 | N/A |
12/31/2018 | 7 | -33 | -35 | -34 | N/A |
9/30/2018 | 8 | -29 | -28 | -27 | N/A |
6/30/2018 | 9 | -25 | -21 | -21 | N/A |
3/31/2018 | 9 | -22 | -19 | -19 | N/A |
12/31/2017 | 10 | -19 | -17 | -17 | N/A |
9/30/2017 | 11 | -16 | N/A | -18 | N/A |
6/30/2017 | 13 | -13 | N/A | -19 | N/A |
3/31/2017 | 14 | -10 | N/A | -17 | N/A |
12/31/2016 | 14 | -7 | N/A | -15 | N/A |
9/30/2016 | 13 | -8 | N/A | -14 | N/A |
6/30/2016 | 12 | -8 | N/A | -13 | N/A |
3/31/2016 | 10 | -9 | N/A | -13 | N/A |
12/31/2015 | 9 | -9 | N/A | -14 | N/A |
12/31/2014 | 6 | -7 | N/A | -15 | N/A |
12/31/2013 | 5 | -7 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IVA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IVA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IVA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IVA's revenue (49.1% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: IVA's revenue (49.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IVA's Return on Equity is forecast to be high in 3 years time